Pular para o conteúdo
Granulomatose com poliangeíte
ORPHA:900CID-10 · M31.3CID-11 · 4A44.A1OMIM 608710DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
heartInício infantilHerança Unknown
Também conhecida comoGranulomatose de WegenerSíndrome de WegenerGPA
Sinônimos clínicos: Granulomatose de Wegener

Vasculite necrosante de pequenos vasos caracterizada pela associação de inflamação da parede do vaso e granulomatose peri e extravascular.

Última verificação: Fonte: sem afirmação sobre o SUS a verificarEm construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

Granulomatose com poliangiite (GPA) é uma condição que causa inflamação que afeta principalmente o trato respiratório (incluindo os pulmões e as vias aéreas) e os rins. Esse distúrbio era anteriormente conhecido como granulomatose de Wegener. Uma característica da GPA é a inflamação dos vasos sanguíneos (vasculite), particularmente dos vasos sanguíneos pequenos e de tamanho médio nos pulmões, nariz, seios nasais, traqueia e rins, embora vasos em qualquer órgão possam estar envolvidos. Poliangiite refere‑se à inflamação de múltiplos tipos de vasos, como pequenas artérias e veias. A vasculite causa cicatrização e morte do tecido nos vasos e impede o fluxo sanguíneo para tecidos e órgãos.

Outra característica da GPA é a formação de granulomas, que são pequenas áreas de inflamação compostas por células do sistema imunológico que auxiliam na reação inflamatória. Os granulomas geralmente ocorrem nos pulmões ou nas vias aéreas de pessoas com esta condição, embora possam aparecer nos olhos ou em outros órgãos. À medida que os granulomas crescem, podem invadir áreas circundantes, causando dano ao tecido.

Os sinais e sintomas da GPA variam de acordo com os tecidos e órgãos afetados pela vasculite. Muitas pessoas com a condição experimentam uma sensação vaga de desconforto (mal‑estar), febre, perda de peso ou outros sintomas gerais da reação imunológica do corpo. Na maioria das pessoas com GPA, a inflamação começa nos vasos do trato respiratório, levando a congestão nasal, sangramentos nasais frequentes, falta de ar ou tosse. Inflamação grave no nariz pode levar a um orifício no tecido que separa as duas narinas (perfuração do septo nasal) ou ao colapso do septo, causando um nariz com ponte afundada (nariz em sela).

Os rins são comumente afetados em pessoas com GPA. O dano ao tecido causado pela vasculite nos rins pode levar a diminuição da função renal, o que pode causar aumento da pressão arterial ou sangue na urina, e insuficiência renal que ameaça a vida. A inflamação também pode ocorrer em outras regiões do corpo, incluindo os olhos, estruturas do ouvido médio e interno, pele, articulações, nervos, coração e cérebro. Dependendo dos sistemas envolvidos, sintomas adicionais podem incluir erupções cutâneas, dor no ouvido interno, articulações inchadas e doloridas, e formigamento ou dormência nos membros.

A GPA é mais comum em adultos de meia‑idade, embora possa ocorrer em qualquer idade. Se não tratada, a condição costuma ser fatal dentro de 2 anos após o diagnóstico. Mesmo após o tratamento, a vasculite pode retornar.

Fonte: MedlinePlus Genetics (NLM/NIH), traduzido
📋
Informacoes curadas por IA — podem conter imprecisoes

Vasculite necrosante de pequenos vasos caracterizada pela associação de inflamação da parede do vaso e granulomatose peri e extravascular.

Pesquisas ativas
33 ensaios
126 total registrados no ClinicalTrials.gov
Publicações científicas
4.857 artigos
Último publicado: 2026 Mar
Medicamentos
5 com registro
Truxima (RITUXIMAB-ABBS), Rituxan (RITUXIMAB), TAVNEOS (AVACOPAN)

Tem tratamento?

✓ 5 medicamentos específicos desta doença (registro ANVISA, FDA ou SUS/CEAF)
Ver detalhes, fases e interações →
TRUXIMA (RITUXIMAB-ABBS)RITUXAN (RITUXIMAB)TAVNEOS (AVACOPAN)RIABNI (RITUXIMAB-ARRX)FASENRA (BENRALIZUMAB)

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
9.0
Europe
Início
Adolescent
+ adult, childhood, elderly
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: M31.3
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫁
Pulmão
14 sintomas
❤️
Coração
9 sintomas
🫘
Rins
9 sintomas
🫃
Digestivo
8 sintomas
👁️
Olhos
6 sintomas
🧬
Pele e cabelo
5 sintomas

+ 56 sintomas em outras categorias

Características mais comuns

90%prev.
Infiltrados pulmonares
Muito frequente (99-80%)
90%prev.
Epistaxe
Muito frequente (99-80%)
90%prev.
Febre
Muito frequente (99-80%)
90%prev.
Isquemia cerebral
Muito frequente (99-80%)
90%prev.
Hematúria
Muito frequente (99-80%)
90%prev.
Morfologia anormal da cavidade oral
Muito frequente (99-80%)
129sintomas
Muito frequente (18)
Frequente (28)
Ocasional (37)
Sem dados (46)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 129 características clínicas mais associadas, ordenadas por frequência.

Infiltrados pulmonaresPulmonary infiltrates
Muito frequente (99-80%)90%
EpistaxeEpistaxis
Muito frequente (99-80%)90%
FebreFever
Muito frequente (99-80%)90%
Isquemia cerebralCerebral ischemia
Muito frequente (99-80%)90%
HematúriaHematuria
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico4.857PubMed
Últimos 10 anos200publicações
Pico2026125 papers
Linha do tempo
2026Hoje · 2026🧪 1976Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

5 genes identificados com associação a esta condição. Padrão de herança: Not applicable.

CTLA4Cytotoxic T-lymphocyte protein 4Major susceptibility factor inAltamente restrito
VIAS BIOLÓGICAS (3)
Co-stimulation by CD28Co-inhibition by CTLA4RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Tecido-específico)
Baço
5.8 TPM
Intestino delgado
4.9 TPM
Pulmão
4.3 TPM
Testículo
2.5 TPM
Sangue
1.8 TPM
OUTRAS DOENÇAS (6)
autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiencysystemic lupus erythematosusgranulomatosis with polyangiitismycosis fungoides
HGNC:2505UniProt:P16410
PTPN22Tyrosine-protein phosphatase non-receptor type 22Major susceptibility factor inTolerante
VIAS BIOLÓGICAS (2)
Phosphorylation of CD3 and TCR zeta chainsTranslocation of ZAP-70 to Immunological synapse
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
50.6 TPM
Baço
13.9 TPM
Sangue
12.7 TPM
Intestino delgado
9.6 TPM
Pulmão
8.7 TPM
OUTRAS DOENÇAS (6)
systemic lupus erythematosusVogt-Koyanagi-Harada diseaseoligoarticular juvenile idiopathic arthritisrheumatoid factor-negative juvenile idiopathic arthritis
HGNC:9652UniProt:Q9Y2R2
HLA-DPA1HLA class II histocompatibility antigen, DP alpha 1 chainMajor susceptibility factor inTolerante
VIAS BIOLÓGICAS (7)
Generation of second messenger moleculesTranslocation of ZAP-70 to Immunological synapsePhosphorylation of CD3 and TCR zeta chainsCo-inhibition by PD-1Downstream TCR signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
807.2 TPM
Baço
365.3 TPM
Pulmão
357.3 TPM
Nervo tibial
187.9 TPM
Tecido adiposo
177.3 TPM
OUTRAS DOENÇAS (1)
granulomatosis with polyangiitis
HGNC:4938UniProt:P20036
PRTN3MyeloblastinMajor susceptibility factor inTolerante
VIAS BIOLÓGICAS (1)
Other interleukin signaling
EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
34.8 TPM
Baço
17.5 TPM
Pulmão
7.2 TPM
Córtex cerebral
3.5 TPM
Brain Frontal Cortex BA9
3.3 TPM
OUTRAS DOENÇAS (1)
granulomatosis with polyangiitis
HGNC:9495UniProt:P24158
HLA-DPB1HLA class II histocompatibility antigen, DP beta 1 chainMajor susceptibility factor inTolerante
VIAS BIOLÓGICAS (7)
Generation of second messenger moleculesTranslocation of ZAP-70 to Immunological synapsePhosphorylation of CD3 and TCR zeta chainsCo-inhibition by PD-1Downstream TCR signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
298.6 TPM
Baço
261.2 TPM
Pulmão
218.9 TPM
Nervo tibial
117.2 TPM
Tecido adiposo
103.4 TPM
OUTRAS DOENÇAS (2)
granulomatosis with polyangiitischronic beryllium disease
HGNC:4940UniProt:P04440

Medicamentos aprovados (FDA)

5 medicamentos encontrados nos registros da FDA americana.

💊 Truxima (RITUXIMAB-ABBS)
💊 Rituxan (RITUXIMAB)
💊 TAVNEOS (AVACOPAN)
💊 Riabni (RITUXIMAB-ARRX)
💊 FASENRA (BENRALIZUMAB)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

145 variantes patogênicas registradas no ClinVar.

🧬 CTLA4: NM_005214.5(CTLA4):c.148_165del (p.Ser50_Ser55del) ()
🧬 CTLA4: NM_005214.5(CTLA4):c.174_175del (p.Cys58_Glu59delinsTer) ()
🧬 CTLA4: NM_005214.5(CTLA4):c.123_124delinsTT (p.Gln42Ter) ()
🧬 CTLA4: NM_005214.5(CTLA4):c.313G>A (p.Gly105Ser) ()
🧬 CTLA4: NM_005214.5(CTLA4):c.406C>G (p.Pro136Ala) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado8
3Fase 324
2Fase 221
1Fase 17
·Pré-clínico40
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 100 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Granulomatose com poliangeíte

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 36 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

23 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07087912 · Safety and Immunogenicity of the Live Attenuated Tetravalent…Recrutando
PHASE4🇧🇷 Brasil
NCT06512883 · A Trial to Investigate Benralizumab in Children With Eosinop…Recrutando
PHASE3🇧🇷 Brasil · 🇨🇦 Canadá · 🇫🇷 França +7
NCT07444567 · Roll-over Study for Participants Who Have Completed a Previo…Recrutando
PHASE3🇦🇷 Argentina · 🇦🇹 Áustria · 🇧🇪 Bélgica +11
NCT07176546 · TAVNEOS for Otolaryngologic Manifestations of Granulomatosis…Recrutando
PHASE2, PHASE3🇺🇸 Estados Unidos
NCT07815886 · Benralizumab Effectiveness in EGPARecrutando
🇮🇹 Itália
NCT06940661 · Obinutuzumab for Remission Induction in Patients With Relaps…Recrutando
PHASE2🇫🇷 França
NCT07138898 · Immunosuppressant Management in Rheumatology Patients Underg…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06983821 · Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-…Recrutando
PHASE3🇨🇦 Canadá
NCT04871191 · Study of Salvage Therapy to Treat Patients With Granulomatos…Recrutando
PHASE3🇫🇷 França
NCT07275190 · The Use of Machine Learning Techniques for the Differential …Recrutando
NA🇮🇹 Itália
NCT06611696 · Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated …Recrutando
PHASE4🇯🇵 Japão
NCT06350110 · Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Sy…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT06581562 · Open-label Single-Center Study to Evaluate the Safety and Ef…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT06298448 · eGPA and Local Inflammation Within the Ear, Nose and Throat …Recrutando
🇳🇱 Países Baixos
NCT05979051 · A Study to Evaluate the Efficacy and Safety of SHR-1703 in S…Recrutando
PHASE2, PHASE3🇨🇳 China
NCT06758271 · Special Drug Use-results Survey for Long-term Use(Avacopan)Recrutando
🇯🇵 Japão
NCT04538937 · Prospective Registry of Eosinophilia With Respiratory Manife…Recrutando
🇦🇹 Áustria
NCT03004326 · Clinical Transcriptomics in Systemic Vasculitis (CUTIS)Recrutando
🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT02967068 · VCRC Tissue RepositoryRecrutando
🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT02593565 · Vasculitis Pregnancy RegistryRecrutando
🇺🇸 Estados Unidos
NCT01241305 · One-Time DNA Study for VasculitisRecrutando
🇨🇦 Canadá · Turkey (Türkiye) · 🇺🇸 Estados Unidos
NCT00315380 · Longitudinal Study for Eosinophilic Granulomatosis With Poly…Recrutando
🇨🇦 Canadá · 🇩🇪 Alemanha · 🇮🇹 Itália +2
NCT07343661 · Beyond EOsinophils: proteoMICS to Identify Potential Biomark…Por convite
PHASE4🇮🇹 Itália

Outros ensaios clínicos

126 ensaios clínicos encontrados, 33 ativos.

Distribuição por fase
NCT07451847 · Comparison of a Strategy Based on Clinico-biological Monitor…Em breve
PHASE4🇫🇷 França
NCT06911775 · Eosinophil Subpopulations in Eosinophilic-associated Disease…Em breve
NCT06868290 · Phase 2 Study Evaluating Rapcabtagene Autoleucel in Particip…Ativo
PHASE2🇧🇷 Brasil · 🇮🇱 Israel · 🇯🇵 Japão +5
NCT05263934 · Efficacy and Safety of Depemokimab Compared With Mepolizumab…Ativo
PHASE3🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇹 Áustria +15
NCT06388941 · Iptacopan in Patients With ANCA Associated VasculitisAtivo
PHASE2🇦🇷 Argentina · 🇦🇺 Austrália · 🇦🇹 Áustria +12
NCT06230354 · Explore the Efficacy and Mechanism of Action of Tezepelumab …Ativo
PHASE2🇬🇧 Reino Unido
NCT06294236 · Study Evaluating SC291 in Subjects With Severe r/r B-cell Me…Ativo
PHASE1🇺🇸 Estados Unidos
NCT06046222 · Trial of Efficacy and Safety of NS-229 Versus Placebo in Pat…Ativo
PHASE2🇨🇦 Canadá · 🇫🇷 França · 🇩🇪 Alemanha +5
NCT05732402 · An Open-label Study of Povetacicept in Autoantibody-Associat…Ativo
PHASE1, PHASE2🇦🇺 Austrália · Puerto Rico · South Korea +1
NCT03919435 · TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis…Ativo
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT03430388 · Yellow Fever Vaccine in Patients With Rheumatic DiseasesConcluído
NA🇧🇷 Brasil
NCT07591753 · Long-Term Safety and Effectiveness of Mepolizumab 300 mg in …Concluído
🇮🇹 Itália
NCT07592104 · Effectiveness on Sino-Nasal Symptoms Of Mepolizumab 300Concluído
🇮🇹 Itália
NCT07712172 · Assessing Granulomatosis With Polyangiitis Activity: 18F-FDG…Concluído
🇮🇳 Índia
NCT05030155 · Study of Mepolizumab-based Regimen Compared to Conventional …Concluído
PHASE3🇫🇷 França
NCT05091333 · FASENRA Regulatory Postmarketing Surveillance in KoreaConcluído
South Korea
NCT05703802 · Establishment of an ELISA for the Recognition of Procalciton…Concluído
🇩🇪 Alemanha
NCT05716334 · Biosimilars of Rituximab in ANCA-associated Vasculitis Compa…Concluído
🇨🇦 Canadá
NCT04551989 · Mepolizumab Long-term Study to Assess Real World Safety and …Concluído
🇯🇵 Japão
NCT04280601 · PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculiti…Concluído
NA🇨🇦 Canadá
NCT04428398 · Urinary T Lymphocytes Predict Renal Flares in Patients With …Concluído
🇩🇪 Alemanha
NCT03895801 · Study of IFX-1 to Replace Steroids in Patients With Granulom…Concluído
PHASE2🇧🇪 Bélgica · 🇨🇿 Tchéquia · 🇫🇷 França +8
NCT03482479 · Low Dose Naltrexone to Improve Physical Health in Patients W…Concluído
PHASE2🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT03698071 · Soluble CD95 Ligand Role in the Pathophysiology of Antineutr…Concluído
NA🇫🇷 França
NCT03557060 · NUCALA® Special Drug Use Investigation (EGPA, Long-term)Concluído
🇯🇵 Japão
NCT03164473 · Maintenance of Remission With Rituximab Versus Azathioprine …Concluído
PHASE3🇫🇷 França
NCT03410290 · Journey of Patients With Vasculitis From First Symptom to Di…Concluído
🇺🇸 Estados Unidos
NCT02807103 · Rituximab in Eosinophilic Granulomatosis With PolyangiitisConcluído
PHASE3🇫🇷 França
NCT02115997 · A Study Evaluating the Safety and Efficacy of Rituximab in C…Concluído
PHASE4🇮🇳 Índia
NCT02507024 · The ANCA Vasculitis Questionnaire (AAV-PRO©)Concluído
🇺🇸 Estados Unidos
NCT02476292 · Impact of Vasculitis on Employment and IncomeConcluído
🇺🇸 Estados Unidos
NCT02108860 · Abatacept for the Treatment of Relapsing, Non-Severe, Granul…Concluído
PHASE3🇨🇦 Canadá · 🇩🇪 Alemanha · 🇮🇪 Irlanda +2
NCT03298061 · Long-term Access Program (LAP) of Mepolizumab for Subjects W…Concluído
PHASE3🇧🇪 Bélgica · 🇨🇦 Canadá · 🇫🇷 França +4
NCT02433522 · Comparison Between a Long Term and a Conventional Maintenanc…Concluído
PHASE3🇫🇷 França
NCT02169219 · Pilot Study of Short-Course Glucocorticoids and Rituximab fo…Concluído
PHASE4🇺🇸 Estados Unidos
NCT02190942 · VCRC Patient Contact Registry Patient-Reported Data Validati…Concluído
🇺🇸 Estados Unidos
NCT01940094 · The Assessment of Prednisone In Remission Trial - Centers of…Concluído
PHASE3🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT01988506 · Induction of Regulatory t Cells by Low Dose il2 in Autoimmun…Concluído
PHASE2🇫🇷 França
NCT01750697 · A Phase IIa Study of Intravenous Rituximab in Pediatric Part…Concluído
PHASE2🇨🇦 Canadá · 🇫🇷 França · 🇩🇪 Alemanha +5
NCT01697267 · Rituximab Vasculitis Maintenance StudyConcluído
PHASE3🇦🇺 Austrália · 🇨🇦 Canadá · 🇨🇿 Tchéquia +7
NCT01663623 · Belimumab in Remission of VASculitisConcluído
PHASE3🇦🇺 Austrália · 🇧🇪 Bélgica · 🇨🇦 Canadá +17
NCT01731561 · Comparison Study of Two Rituximab Regimens in the Remission …Concluído
PHASE3🇫🇷 França
NCT01613599 · An Observational Study of The Safety of MabThera/Rituxan (Ri…Concluído
🇺🇸 Estados Unidos
NCT01862068 · Neutrophils as Prognostic Factors in Granulomatosis With Pol…Concluído
🇫🇷 França
NCT02190929 · Educational Needs of Patients With Systemic VasculitisConcluído
🇺🇸 Estados Unidos
NCT02190916 · Vasculitis Illness Perception (VIP) StudyConcluído
🇺🇸 Estados Unidos
NCT02176070 · Reproductive Health in Men and Women With VasculitisConcluído
🇺🇸 Estados Unidos
NCT00987389 · Plasma Exchange and Glucocorticoids for Treatment of Anti-Ne…Concluído
PHASE3🇦🇺 Austrália · 🇧🇪 Bélgica · 🇨🇦 Canadá +12
NCT01167491 · Study of One Protein Implicated in Wegener DiseaseConcluído
NA🇫🇷 França
NCT00748644 · Efficacy Study of Two Treatments in the Remission of Vasculi…Concluído
PHASE3🇫🇷 França
NCT00468208 · Abatacept in Treating Adults With Mild Relapsing Wegener's G…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT00315393 · Longitudinal Protocol for Granulomatosis With Polyangiitis (…Concluído
🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT00307671 · Treatment of Necrotizing Vasculitides for Patients Older Tha…Concluído
PHASE4🇫🇷 França
NCT00104299 · Rituximab for the Treatment of Wegener's Granulomatosis and …Concluído
PHASE2, PHASE3🇳🇱 Países Baixos · 🇺🇸 Estados Unidos
NCT00103792 · Mycophenolate Mofetil for Treatment of Relapses of Wegener's…Concluído
PHASE3🇳🇱 Países Baixos
NCT00307593 · RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing…Concluído
NA🇫🇷 França
NCT00530075 · Phase II Study on Gusperimus in Patients With Refractory Weg…Concluído
PHASE2🇨🇿 Tchéquia · 🇩🇰 Dinamarca · 🇩🇪 Alemanha +3
NCT00072592 · An Open Label Pilot Study Examining the Use of Rituximab in …Concluído
PHASE1🇺🇸 Estados Unidos
NCT00753103 · Anti-Cytokine Therapy for VasculitisConcluído
PHASE2🇬🇧 Reino Unido
NCT00040248 · Daclizumab to Treat Wegener's GranulomatosisConcluído
PHASE2🇺🇸 Estados Unidos
NCT00005007 · Etanercept for Wegener's GranulomatosisConcluído
PHASE2, PHASE3🇺🇸 Estados Unidos
NCT00138983 · Prevention of Glucocorticoid-Induced Osteoporosis in Rheumat…Concluído
PHASE3🇳🇱 Países Baixos
NCT00004567 · Comparison of Treatments to Maintain Disease Remission in Pa…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00001901 · Etanercept to Treat Wegener's GranulomatosisConcluído
PHASE2🇺🇸 Estados Unidos
NCT00001764 · Mycophenolate Mofetil to Treat Wegener's Granulomatosis and …Concluído
PHASE1🇺🇸 Estados Unidos
NCT00430105 · Pulse Versus Continuous Cyclophosphamide for Induction of Re…Concluído
PHASE2, PHASE3
NCT00001761 · Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00001759 · Assessment of Lung Inflammation in Patients With Atopic Asth…Concluído
🇺🇸 Estados Unidos
NCT00001541 · Analysis of Bronchial Tissue and Fluid in Patients With Wege…Concluído
🇺🇸 Estados Unidos
NCT00001515 · Diagnostic Effectiveness of Virtual BronchoscopyConcluído
PHASE1🇺🇸 Estados Unidos
NCT00001473 · Cyclophosphamide and Prednisone Followed by Methotrexate To …Concluído
🇺🇸 Estados Unidos
NCT00001256 · Steroids and Methotrexate to Treat Systemic VasculitisConcluído
PHASE2🇺🇸 Estados Unidos
NCT00001155 · Treatment of Wegener's Granulomatosis With CyclophosphamideConcluído
PHASE2🇺🇸 Estados Unidos
NCT06231498 · The Epigenomic Signature of Eosinophilic Granulomatosis With…UNKNOWN
NCT05353179 · Study on Pharmacokinetics of Meperizumab Injection and NUCAL…UNKNOWN
EARLY_PHASE1🇨🇳 China
NCT04944524 · Comparison of Tofacitinib and Methotrexate in the Maintained…UNKNOWN
PHASE4🇨🇳 China
NCT04320667 · Urinary T Cell Biomarker for Prediction in ANCA Glomerulonep…UNKNOWN
🇩🇪 Alemanha · 🇬🇧 Reino Unido
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥈Melhor nível de evidência: Ensaio clínico
Timeline de publicações
4.261 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 4.261

#1

[Successful early use of mepolizumab in eosinophilic granulomatosis with polyangiitis presenting with peripheral neuropathy and gastrointestinal bleeding].

Rinsho shinkeigaku = Clinical neurology2026 Mar 14

We report a case of a 55-year-old male with eosinophilic granulomatosis with polyangiitis (EGPA) presenting with peripheral neuropathy and gastrointestinal (GI) bleeding. Despite initial treatment with high-dose intravenous methylprednisolone and intravenous immunoglobulin, the patient's symptoms persisted, and GI bleeding worsened. Capsule endoscopy revealed multiple ulcers and erosions throughout the small intestine, and biopsies from the ileum, cecum, and skin showed marked eosinophilic infiltration. Although peripheral blood eosinophil counts were normalized, tissue eosinophilia remained evident. Early administration of mepolizumab, an anti-IL-5 monoclonal antibody, led to rapid improvement in both GI bleeding and neuropathic symptoms. This case highlights the potential role of tissue-infiltrating eosinophils in EGPA pathogenesis and suggests that mepolizumab may be effective even when blood eosinophil levels are not elevated. Early intervention with mepolizumab may be beneficial in severe or refractory EGPA cases with GI involvement, which are associated with poor prognosis and high relapse rates. Careful monitoring and timely therapeutic decisions are essential for improving outcomes in such patients.

#2

Clinical and Pathological Features of Vasculitic Neuropathy: A Single-Center Study in China.

European journal of neurology2026 Mar

Vasculitic neuropathy (VN) is a disease in which vessel inflammation happens and injures peripheral nerves. Despite increasing awareness, features of VN in mainland China are still understudied. To characterize the clinical, pathological features and outcomes of VN in mainland China, and evaluate clinicopathological correlations: METHODS: We retrospectively reviewed records of VN patients diagnosed pathologically between June 1999 and December 2024, including demographic data, clinical manifestations, biopsy features, and outcomes. 112 patients were totally included. All presented with axonal sensorimotor neuropathy, most commonly involving the tibial (90.63%) and peroneal (87.50%) nerves. Systemic VN (SVN) showed more frequent transmural inflammatory cell infiltration (ICI) than non-systemic VN (NSVN) (p = 0.046). Eosinophilic granulomatosis with polyangiitis (EGPA) was more common in VN without ICI than VN with ICI (p = 0.008). In SVN, the ICI-positive exhibited more severe distal upper limb weakness (p = 0.042) and higher thrombosis rates (p = 0.001) than ICI-negative. Of the 63 patients followed, 62 received glucocorticoids with or without immunosuppressants. Thirteen died from multi-organ complications (12 SVN and 1 NSVN), while others achieved remission. The 5-year all-survival rate was 80.23% (95% CI 66.83%- 88.66%). This first large cohort of VN in mainland China delineates its clinical-pathological features. EGPA showed a lower diagnostic yield on biopsy, suggesting diverse mechanisms of vascular injury. Nerve biopsy remains the diagnostic gold standard. The overall prognosis of VN is relatively favorable, emphasizing the need for early recognition and treatment.

#3

Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology.

PloS one2026

The relationship between leukotriene receptor antagonists (LTRAs) usage and the subsequent occurrence of eosinophilic granulomatosis with polyangiitis (EGPA) remained highly polarizing and controversial in previous studies. We aimed to investigate the risk of EGPA caused by LTRAs and the potential toxicological mechanisms of LTRAs-related EGPA. In this real-world pharmacovigilance study, we collected adverse event (AE) reports of EGPA associated with LTRAs use from the U.S. FDA Adverse Event Reporting System (FAERS), Japanese Adverse Drug Event Reporting (JADER), and Canadian Vigilance Adverse Reaction (CVAR) databases. The reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayesian geometric mean (EBGM) were calculated to quantify the strength of the association between LTRAs and EGPA. The Weibull shape parameter (WSP) test was applied to analyze time-to-onset profiles of EGPA toxicity. Network pharmacology analysis was subsequently performed to identify the central genes to determine the potential mechanisms underlying LTRAs-induced EGPA. LTRAs, including montelukast, zafirlukast, and pranlukast, exhibited a strong association with EGPA in three databases (the lower limit of 95% confidence interval (CI) for ROR > 1, PRR > 2 with χ2 values ≥4, EBGM05 > 2, and IC025 > 0). After excluding corticosteroids as concomitant medication, montelukast remained significantly associated with EGPA in the FAERS database. The median time-to-onset of EGPA associated with LTRAs was 233 (range: 76-660) days, and the WSP test indicated LTRAs had early failure-type profiles. We isolated 81 interactive target genes linking LTRAs to EGPA. Several central genes, including SRC, PTGS2, EDN1, HMOX1, KDR, and OCLN, were revealed via protein-protein interactions analysis and molecular complex detection (MCODE) algorithm. Our study revealed LTRAs could increase the risk of EGPA, and initially explored potential genes and mechanisms of LTRAs-induced EGPA. It is helpful for clinicians to be alerted to the risk of EGPA during LTRAs administration.

#4

Tuberculosis or vasculitis? Granulomatous inflammation of the pancreatic tail as an atypical presentation of granulomatosis with polyangiitis.

BMJ case reports2026 Feb 18

Granulomatosis with polyangiitis (GPA), a subtype of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), is a systemic inflammatory disease that typically affects the respiratory tract and kidneys. However, atypical pancreatic manifestations have been reported, which may present clinically as acute pancreatitis or exocrine insufficiency, and radiologically as pancreatic enlargement or pseudotumour.A female in her 40s presented with nasal crusting and epistaxis. She subsequently developed fever, weight loss, haemoptysis, bilateral pulmonary nodules and a pancreatic tail mass. Pancreatic biopsy revealed caseating granulomatous inflammation, and antitubercular therapy was commenced.On developing haematuria and proteinuria, proteinase 3-ANCA testing and renal biopsy confirmed AAV. Treatment with rituximab and high-dose corticosteroids led to clinical improvement and radiological regression of both pulmonary and pancreatic lesions, consistent with systemic GPA involvement.This case highlights the importance of considering systemic inflammatory disease, alongside infective and malignant aetiologies, when evaluating pancreatic masses or focal pancreatitis with constitutional symptoms and multiorgan involvement.

#5

ANCA-associated vasculitis following sotatercept initiation in a patient with heritable pulmonary arterial hypertension and previously silent eosinophilic granulomatosis with polyangiitis: a case report.

European heart journal. Case reports2026 Feb

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary vascular resistance and right ventricular failure. Sotatercept, a novel activin receptor ligand trap, has demonstrated promising haemodynamic benefits in PAH treatment. Eosinophilic granulomatosis with polyangiitis (EGPA) is an extremely rare, Th2-driven, small-vessel vasculitis, and its overlap with PAH is scarcely reported. We report the case of a woman with heritable PAH initially stabilized with oral therapy. In 2024, after further clinical decline, subcutaneous treprostinil was initiated. Subsequently, sotatercept was added, resulting in brief clinical improvement. Within weeks, however, the patient developed severe eosinophilia and exhibited laboratory and histopathological evidence of p-ANCA-positive necrotizing vasculitis, accompanied by renal and hepatocellular dysfunction. This case suggests that sotatercept's modulation of the TGF-β pathway may unmask latent autoimmune diseases such as EGPA in predisposed individuals. Although the temporal relationship between sotatercept initiation and the onset of vasculitis is compelling, both causality and underlying molecular mechanisms remain to be elucidated. Further studies are necessary to understand the potential immunomodulatory mechanisms of sotatercept.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.886 artigos no totalmostrando 197

2026

Evaluation of the Long-Term Safety of Avacopan in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Real World (AvacoStar): Protocol for a Noninterventional Prospective Cohort Study.

JMIR research protocols
2026

A Unique Case of Granulomatosis With Polyangiitis With Cutaneous Manifestations Developing a Decade Later.

Cureus
2026

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease: A systematic review of an emerging condition.

Autoimmunity reviews
2026

Evolving Therapeutic Strategies in ANCA-Associated Vasculitis: Current Standards and Emerging Targets for GPA and MPA.

Clinical reviews in allergy &amp; immunology
2026

Levofloxacin-induced dyskinesia in an elderly patient with granulomatosis with polyangiitis.

Drug and therapeutics bulletin
2026

TAP1 Deficiency Masquerading as Granulomatosis With Polyangiitis: A Case Report Highlighting the Importance of Genetic Evaluation in Atypical Presentations.

International journal of rheumatic diseases
2026

Benralizumab: An effective alternative in patients with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab.

Medicina clinica
2026

[Risk factors of unfavorable clinical outcome in orbital granulomatosis with polyangiitis].

Vestnik oftalmologii
2026

Eosinophilic granulomatosis with polyangiitis coexisting with multiple myeloma: independent entities or coexistence? A case report.

Frontiers in immunology
2026

Cost effectiveness of avacopan for ANCA-associated vasculitis in China.

Clinical and experimental rheumatology
2026

Risk stratification for renal outcomes in ANCA-associated vasculitides using established scores and histopathological criteria.

Journal of nephrology
2026

Beyond Classification: An Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Case.

Cureus
2026

Anti CD19 targeting CAR T cell therapy in ANCA-associated vasculitis.

Rheumatology (Oxford, England)
2026

Clinical Images: The radiographic life cycle of pulmonary granulomatosis with polyangiitis: from solid nodule to cavitary collapse.

ACR open rheumatology
2026

[Successful early use of mepolizumab in eosinophilic granulomatosis with polyangiitis presenting with peripheral neuropathy and gastrointestinal bleeding].

Rinsho shinkeigaku = Clinical neurology
2026

Clinical and Pathological Features of Vasculitic Neuropathy: A Single-Center Study in China.

European journal of neurology
2026

Advances in the treatment of antineutrophil cytoplasmic antibody associated vasculitis: current recommendations, clinical trials and real word data.

Polish archives of internal medicine
2026

Pulmonary Involvement in ANCA-associated Vasculitis Overlapping with Long-standing Systemic Lupus Erythematosus.

Internal medicine (Tokyo, Japan)
2026

Early benralizumab use for the successful treatment of eosinophilic granulomatosis with polyangiitis-associated peripheral neuropathy: A case report.

Internal medicine (Tokyo, Japan)
2026

Benralizumab reduces sputum ANCA in patients with eosinophilic granulomatosis with polyangiitis.

ERJ open research
2026

Epidemiology of eosinophilic granulomatosis with polyangiitis in northern Spain: A population-based study (2000-2024) and literature review.

Autoimmunity reviews
2026

Predictors of glucocorticoid-free clinical remission in patients with newly diagnosed microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study using a nationwide registry in Japan (J-CANVAS).

Arthritis research &amp; therapy
2026

Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology.

PloS one
2026

Expanding the role of avacopan beyond renal involvement: Clinical insights from two cases.

Modern rheumatology case reports
2026

Anti-Myeloperoxidase (MPO)-Positive Granulomatosis With Polyangiitis Presenting With Pulmonary and Cutaneous Vasculitic Flares in End-Stage Renal Disease: A Diagnostic and Therapeutic Challenge.

Cureus
2026

Granulomatosis with polyangiitis masquerading as a hydatid cyst: a diagnostic pitfall.

Clinical rheumatology
2026

Safety of Immune Checkpoint Inhibitors in Cancer Patients With Preexisting Autoimmune Vasculitis.

ACR open rheumatology
2026

Hepatic Lesions With Eosinophilic Granulomatosis With Polyangiitis.

International journal of rheumatic diseases
2026

Differential Diagnosis of Eosinophilic Lung Diseases.

The journal of allergy and clinical immunology. In practice
2026

Granulomatosis with polyangiitis. A diagnostic challenge in pediatric patients.

Archivos de la Sociedad Espanola de Oftalmologia
2026

Systemic Immunosuppression to Reduce Surgical Intervention in ANCA-Negative Subglottic Stenosis.

The Laryngoscope
2026

A Case of Eosinophilic Granulomatosis with Polyangiitis Emerging During Benralizumab Therapy: Successful Management Through a Switch to Mepolizumab Therapy.

Journal of asthma and allergy
2026

Burden of eosinophilic granulomatosis with polyangiitis by disease phase and steroid-sparing effects of biologics: a real-world retrospective study in Europe.

ERJ open research
2026

A Breach in the Lung: Broncho-Pleural Fistula in the Setting of Granulomatosis With Polyangiitis.

Cureus
2026

ANCA-Negative Granulomatosis With Polyangiitis Mimicking Sinusitis and Rhinoscleroma: A Case Report.

Case reports in medicine
2026

[Autoimmune hearing loss in giant cell arteritis: a clinical case].

Vestnik otorinolaringologii
2026

PET/CT Features of Granulomatosis With Polyangiitis Mimicking Left Lung and Tracheal Malignancy.

Clinical nuclear medicine
2026

Fractional Exhaled Nitric Oxide as a Novel Biomarker of Relapse in Eosinophilic Granulomatosis with Polyangiitis.

American journal of respiratory and critical care medicine
2026

Plasma exchange for severe alveolar hemorrhage in ANCA-associated vasculitis: emulation of a target trial.

American journal of respiratory and critical care medicine
2026

Peripheral ulcerative keratitis (PUK) in autoimmune diseases: a severe ocular manifestation not always associated with systemic disease activity.

European journal of internal medicine
2026

Clinical outcomes of subglottic stenosis in granulomatosis with polyangiitis: results of an international multicenter observational study.

Rheumatology (Oxford, England)
2026

A pharmacovigilance study of rituximab-associated adverse events in immune-mediated kidney diseases and transplant-related kidney diseases.

International journal of surgery (London, England)
2026

ANCA-Negative Granulomatous Polyangiitis Presenting With Isolated Oral and Esophageal Involvement.

ACG case reports journal
2025

An atypical case of granulomatosis with polyangiitis in a 15-year-old girl presenting with pyoderma gangrenosum-like ulcers on the face.

Dermatology online journal
2026

Improved long-term prognosis of eosinophilic granulomatosis with polyangiitis: retrospective analysis of 87 patients after biologic therapy introduction in Japan.

Scientific reports
2026

Pulmonary manifestations of granulomatosis with polyangiitis and microscopic polyangiitis.

Seminars in arthritis and rheumatism
2026

Trends in mortality due to GPA/MPA across Europe: insights from a decade of death registrations.

Rheumatology (Oxford, England)
2026

New insights into clinical spectrum of antineutrophil cytoplasmic autoantibody associated disease.

Current opinion in nephrology and hypertension
2026

Eosinophilic granulomatosis with polyangiitis: recent therapeutic advances.

Current opinion in rheumatology
2026

Effectiveness and safety of rituximab for remission maintenance therapy in microscopic polyangiitis and granulomatosis with polyangiitis in Japan: A retrospective multicenter cohort study (J-CANVAS).

Modern rheumatology
2026

Tuberculosis or vasculitis? Granulomatous inflammation of the pancreatic tail as an atypical presentation of granulomatosis with polyangiitis.

BMJ case reports
2026

Effectiveness of Mepolizumab in Severe Uncontrolled Asthma Associated or Not with EGPA Based on the Exacto Scale and Separ-Remas Criteria.

Journal of asthma and allergy
2026

Structures of proteinase 3 and the CD177 receptor complex reveal a major autoantibody epitope.

EMBO reports
2026

Eosinophils ETosis as a novel contributor to the pathogenesis of granulomatosis with polyangiitis.

Clinical and experimental immunology
2026

Early Strawberry Gingivitis in Granulomatosis with Polyangiitis.

Journal of general internal medicine
2026

Role of biological therapies targeting eosinophils in eosinophilic granulomatosis with polyangiitis: current evidence and future perspectives.

Current medical research and opinion
2026

[When inflammation gets sneaky : unmasking granulomatosis with polyangiitis with [18F]FDG PET/CT].

Revue medicale de Liege
2026

Overcoming challenges: magnetic resonance imaging in the detection and monitoring of rare prostate involvement in granulomatosis with polyangiitis.

Clinical and experimental rheumatology
2026

Fatal Granulomatosis with Polyangiitis Presenting as Medial Longitudinal Fasciculus Syndrome with Gastrointestinal Perforation: An Autopsy Case Report.

JMA journal
2026

Eosinophilic Granulomatosis with Polyangiitis Presenting with Intermittent Claudication.

JMA journal
2026

Association Between Bronchiectasis and Serious Infections in Microscopic Polyangiitis and Granulomatosis With Polyangiitis From the J-CANVAS.

International journal of rheumatic diseases
2026

[RECONSIDERATION OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)].

Arerugi = [Allergy]
2026

Beyond Infection and Malignancy: Diagnostic Pitfalls in Pulmonary Granulomatosis with Polyangiitis.

Cureus
2026

ANCA-associated vasculitis following sotatercept initiation in a patient with heritable pulmonary arterial hypertension and previously silent eosinophilic granulomatosis with polyangiitis: a case report.

European heart journal. Case reports
2025

Case Report: Angioimmunoblastic T-cell lymphoma initially diagnosed as eosinophilic granulomatosis with polyangiitis.

Frontiers in medicine
2026

Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis With Polyangiitis: Findings From a Large European Cohort.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2026

Novel Diagnostic Approaches for Eosinophilic Lung Diseases.

The journal of allergy and clinical immunology. In practice
2026

ANCA testing in real-world clinical practice: diagnostic performance and predictive value in a Spanish cohort.

Rheumatology (Oxford, England)
2026

Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis.

Circulation
2026

Infracordal Stenosis: A Glucocorticoid-Responsive Subtype of Autoimmune Laryngotracheal Stenosis.

The Laryngoscope
2026

First presentation of idiopathic granulomatosis with polyangiitis in an adolescent.

BMJ case reports
2026

Catastrophic antiphospholipid syndrome with eosinophilia mimicking hypereosinophilic syndromes with disseminated intravascular coagulation: a case report.

Journal of medical case reports
2025

Fatal Eosinophilic Pulmonary Vasculitis in a Neonate - The First Documented Case in the English Literature.

Annals of clinical and laboratory science
2026

NS-229, a novel Janus kinase 1 inhibitor, ameliorates eosinophilic vasculitis in an ovalbumin-induced mouse model by modulating multiple cytokine signaling pathways.

The Journal of pharmacology and experimental therapeutics
2026

ANCA-negative EGPA with migratory pulmonary masses: A case report of mepolizumab response and literature review.

Medicine
2026

Validation of the 2022 ACR/EULAR classification criteria for eosinophilic granulomatosis with polyangiitis in a Chinese cohort.

Clinical rheumatology
2025

EGPA presenting as sudden cardiac arrest: a case report and review of cardiac manifestations.

Frontiers in immunology
2025

Case Report: Triple autoimmune overlap: rheumatoid arthritis, systemic lupus erythematosus, and hypereosinophilic asthma with systemic manifestations.

Frontiers in immunology
2026

Immature leukocyte and plasma-induced cell death reveal subclinical immune activation in EGPA patients in remission.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]
2026

Otolaryngologic manifestations in granulomatosis with Polyangitis: A systematic review of clinical presentations and renal correlation.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2026

Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA): Do We Need Immunosuppressives?

The journal of allergy and clinical immunology. In practice
2026

Effectiveness, Tolerability, and Safety of Mepolizumab Injection Spacing in Patients With Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Cohort Study.

Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases
2025

Granulomatosis with Polyangiitis Presenting with Hepatic Involvement.

Cureus
2025

Eosinophilic granulomatosis with polyangiitis related giant coronary aneurysm leading to acute myocardial infarction: a case report.

European heart journal. Case reports
2026

A rare case of mastitis involving granulomatosis with polyangiitis after immune checkpoint inhibitor therapy.

International cancer conference journal
2026

Hepatic granulomas heralding eosinophilic granulomatosis with polyangiitis overlapping with Sjögren's syndrome.

Hepatology forum
2025

A Red Eye in an Elderly Patient: A Case Report Highlighting the Importance of Urgent Diagnosis.

Cureus
2026

Autoimmune Disorders Affecting the Larynx: Review of Laryngoscopic Findings and Approach to Multidisciplinary Management.

The Annals of otology, rhinology, and laryngology
2026

Intracerebral Hemorrhage During the Chronic Phase of Eosinophilic Granulomatosis With Polyangiitis: A Case Report Emphasizing Cerebrovascular Vulnerability.

Clinical case reports
2026

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice.

Allergy
2026

Refractory Gingival Enlargement: A Critical Oral Clue to Early-Stage Granulomatosis With Polyangiitis-A Case Report and Literature Review.

Case reports in dentistry
2025

Comparison of Rituximab and Cyclophosphamide for Induction Therapy in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Systematic Review of Randomized Trials and Comparative Cohort Evidence.

Cureus
2026

Impact of ANCA specificity on risk of cardiovascular events and death in ANCA-associated vasculitis.

RMD open
2026

When Tears Signal Vasculitis: Bilateral Dacryoadenitis as the Initial Manifestation of Granulomatosis with Polyangiitis-Case Report.

Reports (MDPI)
2026

ANCA-associated vasculitis in the United Arab Emirates: a 17-year case series with review from Gulf literature.

Annals of Saudi medicine
2026

Prescription Patterns and Outcomes of Topical Antibiotic Irrigations in Difficult-to-Treat Chronic Rhinosinusitis.

American journal of rhinology &amp; allergy
2025

More Than Five Years of Sustained Remission With Mepolizumab in Adolescent-Onset Eosinophilic Granulomatosis With Polyangiitis: A Case Report.

Cureus
2026

Diagnosis of Dual c- and p-ANCA Vasculitis Following SARS-CoV-2 Infection: A Case Report.

The American journal of case reports
2026

Placoid Lesions in Eosinophilic Granulomatosis with Polyangiitis.

Ophthalmology
2026

Diaphragmatic paralysis in eosinophilic granulomatosis with polyangiitis.

Medicina clinica
2026

Eosinophilic Granulomatosis with Polyangiitis Complicated by Eosinophilic Chronic Rhinosinusitis Successfully Treated with Combination of Mepolizumab and Dupilumab: A Case Report.

Internal medicine (Tokyo, Japan)
2026

Granulomatosis with Polyangiitis.

The New England journal of medicine
2026

Effectiveness of low-dose mepolizumab in refractory eosinophilic granulomatosis with polyangiitis: systemic steroid use and remission.

The Korean journal of internal medicine
2026

Bilateral spontaneous kidney rupture in a patient with polyarteritis nodosa disguising as granulomatosis with polyangiitis.

Polish archives of internal medicine
2026

Unmasking EGPA with near fatal diffuse alveolar haemorrhage in severe eosinophilic asthma under treatment with benralizumab: a case report.

BMC pulmonary medicine
2026

Kidney Transplantation in Childhood-Onset ANCA-Associated Vasculitis: Long-Term Outcomes and Prognostic Factors.

Clinical journal of the American Society of Nephrology : CJASN
2026

Airway immune profiles and therapeutic implications of IGF1 in eosinophilic granulomatosis with polyangiitis.

Nature communications
2026

Granulomatosis with polyangiitis presenting as anophthalmic socket pain.

Orbit (Amsterdam, Netherlands)
2026

Lung-limited granulomatosis with polyangiitis and the importance of early treatment: a case report.

Annals of medicine and surgery (2012)
2026

[Granulomatosis with polyangiitis involving the sinonasal region: a clinicopathological analysis of 22 cases].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2025

Eosinophilic Granulomatosis with Polyangiitis Presenting as Acute Abdomen: A Rare Case Report.

Journal of inflammation research
2025

Granulomatosis With Polyangiitis Presenting With H1N1 Influenza.

Cureus
2025

Evaluation and differential diagnosis of eosinophilia: A tertiary allergy center experience.

Tuberkuloz ve toraks
2026

Similar and yet not quite the same: unmasking distinct type I interferon signatures in ANCA vasculitis.

Kidney international
2026

Atypical presentation of granulomatosis with polyangiitis mimicking metastatic breast cancer.

Kidney international
2025

Eosinophilic Granulomatosis With Polyangiitis Presenting as Mononeuritis Multiplex in a Diabetic Patient: Diagnostic and Therapeutic Challenges.

Cureus
2025

Eosinophilic Granulomatosis With Polyangiitis Presenting as a Mononeuritis Multiplex Mimicking Guillain-Barré Syndrome.

Cureus
2026

The risk of cardiovascular death in systemic immune-mediated diseases: A systematic review and meta-analysis.

American journal of preventive cardiology
2025

Concordance between presenting features and relapse in granulomatosis with polyangiitis: implications for risk assessment and counselling.

RMD open
2026

Severe optic neuropathy as initial manifestation of pachymeningitis hypertrophy from granulomatosis with polyangiitis.

Orbit (Amsterdam, Netherlands)
2025

Plasma Exchange as an Adjunctive Therapeutic Option for Severe and Refractory Antineutrophil Cytoplasmic Antibody-Negative Microscopic Polyangiitis and Granulomatosis with Polyangiitis.

Medicina (Kaunas, Lithuania)
2025

Analyses of Final Trends and Comorbidity of Eosinophilic Granulomatosis with Polyangiitis in Patients Hospitalized in Poland in 2014-2023.

Journal of clinical medicine
2025

Rapamycin Modulates the Polarisation of CD4+ T Cells Towards TH1 Cells in Patients with Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis.

Journal of clinical medicine
2026

Update on antineutrophil cytoplasmic antibody vasculitis.

Current opinion in nephrology and hypertension
2025

Benralizumab: Bringing winds of change to eosinophil-associated diseases.

The World Allergy Organization journal
2025

ANCA-Negative Eosinophilic Granulomatosis With Polyangiitis Presenting With Duodenal Stenosis: A Case Report.

The American journal of case reports
2025

Imaging the Cardiac Infiltration: Granulomatosis with Polyangiitis.

European heart journal. Cardiovascular Imaging
2025

Scleritis and associated systemic diseases: contribution of systemic examination, follow-up, and additional investigations.

Journal of ophthalmic inflammation and infection
2025

Pyoderma gangrenosum associated with granulomatosis with polyangiitis: a case report.

Journal of medical case reports
2025

Methotrexate in the Management of Laryngotracheal Stenosis: A Narrative Review.

Journal of voice : official journal of the Voice Foundation
2025

Eosinophilic granulomatosis with polyangiitis diagnosed during tezepelumab treatment for severe asthma: A case report.

Allergology international : official journal of the Japanese Society of Allergology
2025

Anti-Programmed Death-Ligand 1 Antibody-Associated Eosinophilic Granulomatosis with Polyangiitis in Non-Small Cell Lung Cancer: A Case Report.

Internal medicine (Tokyo, Japan)
2026

A case of antineutrophil cytoplasmic antibody-associated vasculitis and sclerosing mediastinitis.

Modern rheumatology case reports
2026

Shifting Sands or ANCA-ed in Place? The Epidemiology of ANCA-Associated Vasculitis over 2 Decades at a Large Tertiary Centre.

Glomerular diseases
2025

Granulomatosis With Polyangiitis (Wegener Granulomatosis): Then and Now.

Archives of pathology &amp; laboratory medicine
2026

Serum Metrnl as a potential biomarker for renal involvement in ANCA-associated vasculitis.

Clinical and experimental immunology
2025

Updated treatment approaches for eosinophilic granulomatosis with polyangiitis: A systematic scoping review.

Modern rheumatology
2025

Anti-proteinase 3 Antibody (PR3)-Anti-neutrophil Cytoplasmic Antibody (ANCA)-Positive Vasculitis: A Rare Presentation in a 90-Year-Old Female.

Cureus
2026

Overview of Biologics Targeting Type 2 Inflammation in Respiratory Disease.

The journal of allergy and clinical immunology. In practice
2025

Inside GEMA 5.5: Expert Insights on the Latest Changes in Asthma Management.

Archivos de bronconeumologia
2026

Critical limb Ischaemia in granulomatosis with polyangiitis: a rare but severe complication.

Modern rheumatology case reports
2025

Venous Thromboembolism May Be Increased in the Early Phases of ANCA-Associated Vasculitis and Could Be Associated With a High Body Mass Index: TR-VaS Experience.

International journal of rheumatic diseases
2026

Sclerosing mesenteritis as a manifestation of granulomatosis with polyangiitis: expanding the disease spectrum.

Rheumatology (Oxford, England)
2025

Eosinophilic Granulomatosis With Polyangiitis Presenting With Syphilitic-Like Palmar Erythema.

International journal of rheumatic diseases
2025

Post-COVID-19 shifts in granulomatosis with polyangiitis: epidemiology, clinical features, and predictors in Iran.

Annals of medicine and surgery (2012)
2025

Nanomedicine-driven microRNA therapy: a precision approach for eosinophilic granulomatosis with polyangiitis.

Annals of medicine and surgery (2012)
2025

Bilateral Ischaemic Stroke in Eosinophilic Granulomatosis With Polyangiitis.

Cureus
2026

Overlapping forms of granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis: Insights from a European multicenter study.

Journal of internal medicine
2025

A case report of eosinophilic granulomatosis with polyangiitis in children with cerebella infarction as the first symptom and literature review.

Frontiers in immunology
2025

Effective Use of Mepolizumab in a Rare Case of Eosinophilic Granulomatosis With Polyangiitis Complicated by Pulmonary Tuberculosis.

Cureus
2025

Angiolymphoid Hyperplasia With Eosinophilia Vs Kimura Disease: Continuum of the Same Disease or a Distinct Entity-A Case Report With Literature Review.

Case reports in medicine
2025

Circulating peripheral helper T cells are expanded and associate with disease activity in granulomatosis with polyangiitis.

Arthritis research &amp; therapy
2025

Dual pathogenesis and treatment approaches for eosinophilic granulomatosis with polyangiitis: a comprehensive review.

Reumatologia
2025

RESER/NVAN: Spanish Registry of patients with ANCA- associated vasculitis: objectives and methodology.

Reumatologia clinica
2026

Adjunctive dual biologic therapy for persistent nasal symptoms in eosinophilic granulomatosis with polyangiitis (EGPA).

American journal of otolaryngology
2025

Tuberculosis or GPA? An Unusual, Multifocal Granulomatosis With Polyangiitis of the Head and Neck.

Ear, nose, &amp; throat journal
2025

Lupus vorax: A rare case of facial tuberculosis in a patient with Noonan syndrome.

IDCases
2025

Acute Eosinophilic Myocarditis and Heart Failure As the First Manifestation of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in an Asthmatic Patient: A Diagnostic Challenge.

Cureus
2025

Dermatomyositis and microscopic polyangiitis overlap: a case-based review.

Rheumatology international
2025

Prediction of relapses in patients with small vessel vasculitides: a multicenter cohort study on histopathological risk patterns.

Rheumatology international
2025

Clinical profile and outcome of patients with ANCA-associated vasculitis with special reference to vasculitis damage index: a longitudinal observational study.

Rheumatology international
2026

Association of Individual or Family History of Autoimmune Disease With Future Development of Type 1 Diabetes.

Diabetes/metabolism research and reviews
2026

Glucocorticoid-free remission with simultaneous mepolizumab and rituximab in life-threatening PR3-ANCA-positive eosinophilic granulomatosis with polyangiitis: a case report and literature review.

Clinical rheumatology
2026

Eosinophilic granulomatosis with polyangiitis mimicking giant cell arteritis.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
2025

Granulomatosis With Polyangiitis Presenting as a Rapidly Enlarging Choroidal Mass: A Case Report.

Cureus
2026

Primary hypophysitis: Classification review.

Journal of neuropathology and experimental neurology
2026

Prediction model to identify patients with hypereosinophilic syndrome using real-world data.

The journal of allergy and clinical immunology. Global
2025

Hypereosinophilic syndrome with pulmonary and hepatic involvement mimicking autoimmune disease.

Oxford medical case reports
2025

Granulomatosis With Polyangiitis (GPA) Presenting With Painless Scleritis and Ocular Hypertension: Case Report.

Case reports in immunology
2025

Molecular Pathogenesis and Targeted Therapies in Eosinophilic Granulomatosis with Polyangiitis: An Updated Review.

International journal of molecular sciences
2025

PR3-ANCA Positive Behçet's Disease with Severe Multisystem Involvement: A Diagnostic Challenge.

Diagnostics (Basel, Switzerland)
2025

Abdominal pain as the sole initial manifestation of ANCA-positive EGPA with myocarditis: a case report and literature review.

BMC cardiovascular disorders
2026

How to choose a biologic agent considering comorbidities of bronchial asthma.

Respiratory investigation
2025

ANCA-negative Pauci-immune Vasculitis, an Often-missed Clinical Entity: A Case Report.

The Journal of the Association of Physicians of India
2026

Early Diagnosis and Treatment in Patients With Eosinophilic Granulomatosis With Polyangiitis.

The journal of allergy and clinical immunology. In practice
2025

Sexual Function in Patients With Systemic Vasculitis: An Overlooked Aspect of Patient Care. Results From a Cross-sectional Study.

Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases
2025

Distinct predictors of peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitis: KEIO-vasculitis cohort.

Seminars in arthritis and rheumatism
2025

Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis.

Annals of the rheumatic diseases
2025

Coronary vasospasms and other cardiac manifestations in Eosinophilic Granulomatosis with Polyangiitis: Clinical impact and frequency in a monocentre study of 103 patients.

RMD open
2025

Epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis in Lithuania, 2012-2021: a retrospective cohort study.

BMJ open
2026

Estimation of Health Utility Values for Eosinophilic Granulomatosis With Polyangiitis.

PharmacoEconomics - open
2025

Clinical, Biomarker, and Radiological Progression from Asthma to Systemic Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Study.

Journal of asthma and allergy
2026

Ulcerative colitis complicated by granulomatosis with polyangiitis treated with tacrolimus.

Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
2026

Coronary Vasospasm in Eosinophilic Granulomatosis With Polyangiitis Presenting as Acute Coronary Syndrome Treated With Anti-IL-5.

JACC. Case reports
2025

Cardiac amyloidosis presenting as right ventricular failure: a case report.

QJM : monthly journal of the Association of Physicians
2026

Current definition of remission in eosinophilic granulomatosis with polyangiitis (EGPA) and future perspectives.

Allergology international : official journal of the Japanese Society of Allergology
2025

Modification of 2022 ACR/EULAR ANCA-associated vasculitis classification criteria in a Japanese cohort (J-CANVAS).

Clinical and experimental rheumatology
2025

Loeffler endocarditis in hypereosinophilic syndrome, the paradox of absent peripheral eosinophilia: a case report.

European heart journal. Case reports
2025

Granulomatosis with Polyangiitis (GPA) in a Polish Tertiary Centre (2010-2025): Sex-Stratified Phenotypes, Serology, and Evolving Treatment Patterns.

Journal of clinical medicine
2025

Phenotype, serotype, and data-driven clustering reveal complementary dimensions of heterogeneity in ANCA-associated vasculitis: a multicentre Japanese cohort (J-CANVAS).

Rheumatology international
2025

Chronic rhinosinusitis is a risk factor for interstitial lung disease in Sjogren's syndrome.

BMC pulmonary medicine
2025

Histoplasmosis-Associated Hemophagocytic Lymphohistiocytosis in the Setting of Granulomatosis With Polyangiitis.

Journal of medical cases
2025

Granulomatosis With Polyangiitis Manifesting With Diabetes Insipidus and Cranial Nerve Involvement: A Case Report and Review of the Literature.

Clinical case reports
2025

Case Report: Sequential use of tezepelumab and mepolizumab for eosinophilic otitis media in EGPA: a steroid-sparing strategy.

Frontiers in allergy
2025

Combined intracavitary, systemic antifungal and surgical treatment of Chronic Pulmonary Aspergillosis: experience from an immunocompromised patient.

Medical mycology case reports
2025

Benralizumab for adults with rare and off-label eosinophilic disorders: a 52-week prospective, single-center study.

Frontiers in immunology
2026

Saddle Nose Deformity in Granulomatosis With Polyangiitis: Clinical and Radiologic Predictors From a Multicenter Cohort.

International forum of allergy &amp; rhinology
Ver todos os 2.886 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Granulomatose com poliangeíte.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Granulomatose com poliangeíte e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

É uma vasculite rara que provoca inflamação destrutiva nos vasos de pequeno calibre e gera lesões granulomatosas. Seu envolvimento costuma ser mais acentuado nas vias aéreas e nos rins.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

10 publicações do grafo RarasNet (PubMed) · 8 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. ORPHA:900
    Orphanet
  2. GARD:7880
    GARD (NIH)
  3. Q1161568
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Granulomatose com poliangeíte. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/granulomatose-com-poliangeite

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Granulomatose com poliangeíte
Compêndio · Raras BR

Granulomatose com poliangeíte

ORPHA:900 · MONDO:0012105
Prevalência
1-9 / 100 000
Herança
Not applicable
CID-10
M31.3 · Granulomatose de Wegener
CID-11
Ensaios
33 ativos
Início
Adolescent, Adult, Childhood, Elderly
Prevalência
9.0 (Europe)
MedGen
UMLS
C0043092
EuropePMC
Wikidata
Wikipedia
Papers 10a
Evidência
🥈 Ensaio clínico

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Genética mendeliana
fonte: OMIM
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Medicamentos aprovados FDA
fonte: FDA OpenFDA
Rara